SLC5A2 and heart failure: Moreover, based on the results of two clinical trials (DAPA-HF and EMPEROR-Reduced), SGLT2 inhibitors are now recommended for the treatment of heart failure with reduced ejection fraction in association with standard treatments regardless of the presence of diabetes mellitus (5).